AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, placebo controlled, multi-center study to
estimate the improvement in progression free survival (PFS) and evaluate the safety and
tolerability of AMG 386 in combination with sorafenib in the treatment of subjects with
advanced clear cell carcinoma of the kidney.